SCHEMBL4828448

SCHEMBL4828448

O=C(C=NO)c1ccncc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
HTT P42858 1/20 0.48
NAPRT Q6XQN6 1/20 0.48
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
PFKFB3 Q16875 2/20 0.43
CYP1A2 P05177 5/20 0.42
CYP2D6 P10635 5/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MPO P05164 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CYP2A6 P11509 1/20 0.42
CYP1A1 P04798 3/20 0.41
CYP1B1 Q16678 3/20 0.41
GPR52 Q9Y2T5 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GAA P10253 1/20 0.41
LTA4H P09960 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828445 1.00 ALDH1A1 (0.49) ALDH1A1HTTNAPRTMEN1KMT2A
Benzene SCHEMBL27436197 0.77 ALDH1A1 (0.56) ALDH1A1HTTNAPRTMEN1KMT2A
SCHEMBL105986 0.77 ALDH1A1 (0.56) ALDH1A1HTTNAPRTMEN1KMT2A
SCHEMBL1370683 0.77 ALDH1A1 (0.56) ALDH1A1HTTNAPRTMEN1KMT2A
SCHEMBL2680021 0.77 ALDH1A1 (0.56) ALDH1A1HTTNAPRTMEN1KMT2A
SCHEMBL6997673 0.77 HTT (0.67) ALDH1A1HTTNAPRTMEN1KMT2A
SCHEMBL6997670 0.77 HTT (0.67) ALDH1A1HTTNAPRTMEN1KMT2A
Water SCHEMBL27459091 0.76 ALDH1A1 (0.54) ALDH1A1HTTNAPRTMEN1KMT2A
SCHEMBL4452292 0.76 ALDH5A1 (0.56) ALDH1A1HTTMEN1KMT2ACYP3A4
Ammonia Solution, Strong SCHEMBL27875840 0.76 ALDH1A1 (0.54) ALDH1A1HTTNAPRTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449484-B2 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-11 US disclosed
EP-1343779-B1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-27 EP disclosed
US-20060166988-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2006-07-27 US disclosed
US-20040053943-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2004-03-18 US disclosed
EP-1343779-A4 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1343779-A2 NOVEL COMPOUNDS SmithKline Beecham Corporation (US) 2003-09-17 EP disclosed
WO-2002039954-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053943-A1 Novel compounds TIE1, TEK, VEGFA ALDH1A1 610/4885HTT 3674/4885NAPRT 3072/4885
US-20060166988-A1 Novel compounds TIE1, TEK, VEGFA ALDH1A1 610/4885HTT 3674/4885NAPRT 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.